In June 2012, a study, published in the New England Journal of Medicine, reported that that birth control products containing combined estrogen-progestin, such as Yaz or Yasmin, may double a woman’s risk of stroke and heart attack compared to other hormonal contraceptives. The study, based on data compiled over 15 years from more than 1.5 million women between the ages of 15 and 49, compared the heart risks from other forms of hormonal contraception. The researchers found that women using birth control which combined low-dose estrogen with progestin, such as Yaz or Yasmin, were up to twice as likely to suffer a heart attack or stroke as a woman who did not use a hormonal contraception. The study went on to further note that women with high blood pressure or diabetes or were over the age of 35 were at an even higher risk.
The labels on Yaz and Yasmin were revised in April 2012, following the December 2011, ruling by the Federal Drug and Administration (FDA) that the label warnings on Yaz and Yasmin regarding the risk of blood clots were inadequate.
If you have suffered a Yaz stroke, heart attack, deep vein thrombosis or pulmonary embolism while taking YAZ® or Yasmin®, contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, to help you assess any claims that you might have against the YAZ® or Yasmin® manufacturers.